124.04

0.63% 0.9749

Sarepta Therapeutics Inc (SRPT)

Overview News Price History Option Chain Financials Why SRPT Down? Discussions Forecast Stock Split

Sarepta Therapeutics Inc stock is traded at $124.04, with a volume of 332.76K. It is up +0.63% in the last 24 hours and up +2.86% over the past month. Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of company's product candidates are at an early stage of development.

Previous Close:

$123.07

Open:

$123

24h Volume:

332.76K

Relative Volume:

0.38

Market Cap:

$11.74B

Revenue:

$1.50B

Net Income/Loss:

$47.30M

P/E Ratio:

-15.84

EPS:

-7.83

Net Cash Flow:

$-527.92M

1W Performance:

-4.89%

1M Performance:

+2.86%

6M Performance:

-7.35%

1Y Performance:

+58.75%

1-Day Range:

$121.18

$125.15

1-Week Range:

$121.01

$130.85

52-Week Range:

$75.85

$173.25

Sarepta Therapeutics Inc Stock (SRPT) Company Profile

Name

Sarepta Therapeutics Inc

Sector

Healthcare (1181)

Industry

Biotechnology (680)

Phone

617-274-4000

Address

215 FIRST STREET, CAMBRIDGE, MA

Employee

1,314

Twitter

@sarepta

Next Earnings Date

2024-11-06

Latest SEC Filings

SRPT's Discussions on Twitter

Sarepta Therapeutics Inc Stock (SRPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-31-24	Initiated	BMO Capital Markets	Outperform
Dec-13-23	Resumed	Citigroup	Buy
Dec-12-23	Initiated	Deutsche Bank	Buy
Nov-21-23	Initiated	Wedbush	Outperform
Oct-31-23	Downgrade	Cantor Fitzgerald	Overweight → Neutral
Oct-31-23	Downgrade	Oppenheimer	Outperform → Perform
Jun-23-23	Downgrade	Evercore ISI	Outperform → In-line
Apr-26-23	Initiated	SMBC Nikko	Outperform
Apr-04-23	Initiated	Citigroup	Buy
Mar-01-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Dec-22-22	Reiterated	BTIG Research	Buy
Dec-16-22	Upgrade	UBS	Neutral → Buy
Apr-04-22	Resumed	Cantor Fitzgerald	Overweight
Jan-05-22	Reiterated	Needham	Buy
Dec-09-21	Upgrade	Oppenheimer	Perform → Outperform
Nov-05-21	Upgrade	JP Morgan	Neutral → Overweight
Sep-15-21	Upgrade	Guggenheim	Neutral → Buy
Aug-05-21	Upgrade	JP Morgan	Underweight → Neutral
Jun-15-21	Initiated	BTIG Research	Buy
Apr-26-21	Resumed	Credit Suisse	Neutral
Jan-12-21	Downgrade	Citigroup	Buy → Neutral
Jan-11-21	Downgrade	UBS	Buy → Neutral
Jan-08-21	Downgrade	JP Morgan	Overweight → Underweight
Jan-08-21	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-08-21	Downgrade	Raymond James	Outperform → Mkt Perform
Nov-11-20	Initiated	Berenberg	Hold
Oct-28-20	Initiated	UBS	Buy
Aug-25-20	Initiated	Raymond James	Outperform
Aug-20-20	Downgrade	Credit Suisse	Outperform → Neutral
Mar-31-20	Initiated	Mizuho	Buy
Nov-01-19	Initiated	Guggenheim	Buy
Aug-21-19	Reiterated	Needham	Buy
Jul-09-19	Reiterated	Morgan Stanley	Overweight
Jul-01-19	Reiterated	RBC Capital Mkts	Outperform
Apr-12-19	Initiated	Evercore ISI	Outperform
Mar-11-19	Reiterated	Credit Suisse	Outperform
Oct-12-18	Initiated	Bernstein	Outperform
Oct-01-18	Initiated	Cantor Fitzgerald	Overweight
Sep-26-18	Reiterated	RBC Capital Mkts	Outperform
Sep-14-18	Resumed	BofA/Merrill	Buy
Sep-06-18	Initiated	Credit Suisse	Outperform
Aug-01-18	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Jun-21-18	Reiterated	Robert W. Baird	Outperform
Jun-20-18	Reiterated	Needham	Buy
Jun-19-18	Reiterated	H.C. Wainwright	Buy

View All

Sarepta Therapeutics Inc Stock (SRPT) Latest News

03:45 AM

Allspring Global Investments Holdings LLC Sells 21,269 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

03:45 AM

Nov 04, 2024

Emerald Advisers LLC Has $1.04 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 04, 2024

Nov 01, 2024

Gladstone Institutional Advisory LLC Acquires 26,900 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Nov 01, 2024

Oct 31, 2024

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

Oct 31, 2024

Interesting SRPT Put And Call Options For December 13th - Nasdaq

Oct 31, 2024

Pinnacle Associates Ltd. Has $11.48 Million Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Oct 31, 2024

Oct 30, 2024

Sarepta Therapeutics (SRPT) Scheduled to Post Quarterly Earnings on Wednesday - MarketBeat

Oct 30, 2024

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Acquired by abrdn plc - MarketBeat

Oct 30, 2024

Oct 29, 2024

China Universal Asset Management Co. Ltd. Has $2.29 Million Stock Position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) - MarketBeat

Oct 29, 2024

Oct 28, 2024

Stock Market Movers Today • Top Gainers & Losers - Benzinga

Oct 28, 2024

Oct 27, 2024

Sarepta’s Recent Elevidys Presentations Leave Duchenne Community Wanting - BioSpace

Oct 27, 2024